143 related articles for article (PubMed ID: 35792020)
1. Serum HDAC4 level in rheumatoid arthritis: Longitudinal change during treatment and correlation with clinical outcomes.
Mou X; Jin Y; Jin D; Guan J; Zhang Q
J Clin Lab Anal; 2022 Aug; 36(8):e24594. PubMed ID: 35792020
[TBL] [Abstract][Full Text] [Related]
2. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 in rheumatoid arthritis: Longitudinal change after treatment and correlation with treatment efficacy of tumor necrosis factor inhibitors.
Wang F; Liu G; Xiang L; Yuan J; Tao Y; Zhang L; Zhang A; Chang X
J Clin Lab Anal; 2022 Jun; 36(6):e24449. PubMed ID: 35500150
[TBL] [Abstract][Full Text] [Related]
3. Serum CDC42 is increased during tumor necrosis factor inhibitor treatment, and its elevation correlates with satisfactory treatment response in rheumatoid arthritis patients.
Yang Y; Wu B; Tian P; Huang L
Int J Rheum Dis; 2023 Aug; 26(8):1521-1528. PubMed ID: 37382403
[TBL] [Abstract][Full Text] [Related]
4. JKAP correlates with lower disease risk and inflammation, and its increment during etanercept treatment associates with commendable treatment efficiency in rheumatoid arthritis patients.
Mou XY; Jin D; Zhang Q; Guan JT; Jin Y
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2654-2661. PubMed ID: 33829452
[TBL] [Abstract][Full Text] [Related]
5. JNK pathway-associated phosphatase associates with rheumatoid arthritis risk, disease activity, and its longitudinal elevation relates to etanercept treatment response.
Sun L; Tu J; Chen X; Dai M; Xia X; Liu C; Zhou Y
J Clin Lab Anal; 2021 Apr; 35(4):e23709. PubMed ID: 33547838
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal monitor of Jun N-terminal kinase pathway associated phosphatase reflects clinical efficacy to triple conventional disease-modifying anti-rheumatic drugs treatment in rheumatoid arthritis patients.
Song D; Zhu X; Wang F; Sun J
Inflammopharmacology; 2021 Aug; 29(4):1131-1138. PubMed ID: 34254203
[TBL] [Abstract][Full Text] [Related]
7. Blood HDAC4 Variation Links With Disease Activity and Response to Tumor Necrosis Factor Inhibitor and Regulates CD4+ T Cell Differentiation in Ankylosing Spondylitis.
Dou B; Ma F; Jiang Z; Zhao L
Front Med (Lausanne); 2022; 9():875341. PubMed ID: 35602496
[TBL] [Abstract][Full Text] [Related]
8. Inter-alpha-trypsin inhibitor heavy chain 4: A serologic marker relating to disease risk, activity, and treatment outcomes of rheumatoid arthritis.
He K; He S; Su M
J Clin Lab Anal; 2022 Mar; 36(3):e24231. PubMed ID: 35064701
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA GAS5 suppresses rheumatoid arthritis progression via miR-128-3p/HDAC4 axis.
Peng T; Ji D; Jiang Y
Mol Cell Biochem; 2021 Jun; 476(6):2491-2501. PubMed ID: 33611674
[TBL] [Abstract][Full Text] [Related]
10. Correlation of Ultrasound Synovitis Joint Count with Disease Activity and Its Longitudinal Variation with Treatment Response to Etanercept in Rheumatoid Arthritis.
Wang C; Qin Y; Xu J; Li G; Lei J; Zhang C; Deng H
Ultrasound Med Biol; 2021 Sep; 47(9):2543-2549. PubMed ID: 34175145
[TBL] [Abstract][Full Text] [Related]
11. Blood MALT1, Th1, and Th17 cells are dysregulated, inter-correlated, and correlated with disease activity in rheumatoid arthritis patients; meanwhile, MALT1 decline during therapy relates to treatment outcome.
Ye Z; Chen L; Fang Y; Zhao L
J Clin Lab Anal; 2022 Jan; 36(1):e24112. PubMed ID: 34788483
[TBL] [Abstract][Full Text] [Related]
12. Circular RNA circ_0008360 Inhibits the Proliferation, Migration, and Inflammation and Promotes Apoptosis of Fibroblast-Like Synoviocytes by Regulating miR-135b-5p/HDAC4 Axis in Rheumatoid Arthritis.
Hao J; Chen Y; Yu Y
Inflammation; 2022 Feb; 45(1):196-211. PubMed ID: 34462830
[TBL] [Abstract][Full Text] [Related]
13. miR-138 activates NF-κB signaling and PGRN to promote rheumatoid arthritis via regulating HDAC4.
Shao L; Hou C
Biochem Biophys Res Commun; 2019 Oct; 519(1):166-171. PubMed ID: 31492495
[TBL] [Abstract][Full Text] [Related]
14. Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study.
Perrotta FM; De Socio A; Scriffignano S; Lubrano E
Clin Rheumatol; 2018 Jun; 37(6):1449-1455. PubMed ID: 29468339
[TBL] [Abstract][Full Text] [Related]
15. [Significance of v-raf murine sarcoma viral oncogene homologue B1 in rheumatoid arthritis].
Jin YJ; Sun L; Yang L; Xing R; Liu XY
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):947-950. PubMed ID: 27987495
[TBL] [Abstract][Full Text] [Related]
16. IL-1β, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients.
Zhang B; Jiang W
Inflammopharmacology; 2019 Dec; 27(6):1123-1130. PubMed ID: 31463666
[TBL] [Abstract][Full Text] [Related]
17. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
[TBL] [Abstract][Full Text] [Related]
18. The relationship of blood CDC42 level with Th1 cells, Th17 cells, inflammation markers, disease risk/activity, and treatment efficacy of rheumatoid arthritis.
Li Y; Yang W; Wang F
Ir J Med Sci; 2022 Oct; 191(5):2155-2161. PubMed ID: 34859333
[TBL] [Abstract][Full Text] [Related]
19. A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers.
Pomirleanu C; Ancuta C; Miu S; Chirieac R
Clin Rheumatol; 2013 May; 32(5):665-70. PubMed ID: 23292520
[TBL] [Abstract][Full Text] [Related]
20. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis.
Steiner G; Studnicka-Benke A; Witzmann G; Höfler E; Smolen J
J Rheumatol; 1995 Mar; 22(3):406-12. PubMed ID: 7783054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
